Abstract: Novel hydrophobic psuedo-peptides of formula I ##STR1## wherein R.sub.1 is lower alkyl or -CH.sub.2 CONR.sub.6 R.sub.7 ; R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are independently lower alkyl, cycloalkyl lower alkyl, aryl lower alkyl, heteroaryl lower alkyl, aryl lower alkoxy, substituted aryl lower alkyl, wherein the aryl portion is substituted with 1-3 substituents independently selected from lowr alkyl, hydroxyl, lower alkoxy and halogeno, substituted heteroaryl lower alkyl wherein the substituents on the heteroaryl portion are as defined for aryl lower alkyl, substituted cycloalkyl lower alkyl, wherein the substituents on the cycloalkyl portion are as defined for aryl lower alkyl, and substituted aryl lower alkoxy wherein the substituents are as defined for aryl lower alkyl;R.sub.6 and R.sub.7 are independently hydrogen or lower alkyl;X.sub.1, X.sub.2, X.sub.3, X.sub.4 and X.sub.5 are independently ##STR2## cis or trans --CR.sub.8 .dbd.CR.sub.9 --, --CHR.sub.8 CHR.sub.9 --, --CH.sub.2 NR.sub.

Abstract: Pharmaceutical compositions and a method for reducing intraocular pressure by topically applying a carboxyalkyl dipeptide are disclosed.

Abstract: A method of enhancing transdermal delivery of a pharmaceutically active drug from a transdermal delivery system as well as a transdermal delivery system capable of providing a desirable flow interface between the delivery system and the skin surface are disclosed. The method involves pre-treating an area of skin with an anticholinergic agent in an amount sufficient to have a local antisecretory effect on the area treated, such amount being insufficient to cause systemic effects; and applying the transdermal delivery system to the pre-treated area. The delivery system of the present invention is comprised of a carrier means, a pharmaceutically active drug and an anticholinergic agent. With both the method and the delivery system, the anticholinergic agent is preferably a quaternary ammonium salt which is itself transdermally delivered to the area beneath the delivery system in an amount sufficient to suppress perspiration in that area.

Abstract: A method of treating actinic keratoses with alpha.sub.2 interferon is disclosed.

Abstract: A long acting diltiazem formulation is disclosed that comprises more than 35 percent by weight of a swellable hydrophilic polymer.Release rate is also controlled by the application of diffusion controlled membrane to the matrix tablet containing swellable hydrophilic polymers. The diffusion rate through the membrane depends upon the composition or ratio of hydrophilic to hydrophobic coating agent.

Abstract: Stable sustained release wax- and polymer-coated drug-ion exchange resin complexes especially useful in preparing oral suspensions are disclosed.

Abstract: An immediate release diltiazem tablet is disclosed that exhibits an unexpectedly rapid bioavailability profile when the active ingredient is diltiazem.

Abstract: This invention relates to monoclonal antibodies to interferon alpha and to hybridomas producing such antibodies. These antibodies are preferably of the immunoglobulin subclass IgGl and preferably do not bind to alpha or alpha interferon. They can be used in assaying, purifying or isolating proteins, such as interferon alpha, for which they are specific.

Abstract: Antihypertensive phosphodiesterase inhibitors having an optionally substituted purine derivative portion and a benzo- or cyclopenta-furan derivative portion are disclosed.

Abstract: An atomizing nozzle for use in a fluidized coating bed includes an elongated hollow tube defining a chamber therein, the tube including an atomizing end in fluid communication with the chamber and a supply end; an air supply port at the supply end in fluid communication with the chamber; a coating liquid supply port at the supply end, the coating liquid supply port being separated from the air supply port; and a flow control tube extending within the hollow tube between the liquid supply port and the atomizing end, for supplying the coating liquid to be atomized to the atomizing end, the flow control tube having an reduced diameter inner bore providing a controlled flow constriction to the liquid travelling from the liquid supply port to the atomizing end so as to supply the coating liquid from the coating liquid supply port to the atomizing end with a controlled flow constriction, such that there is no need to provide a metering pump or flow meter for each atomizing nozzle of the fluidized coating bed and co

Abstract: An assembly for coupling a Hewlett-Packard Model HP 7673A autosampler mounted on a mounting plate to a Varian VISTA 6000 Model gas chromatograph having an injection site, includes a first bracket secured to the gas chromatograph on one side of the injection site and a second bracket secured to the gas chromatograph on the opposite side of the injection site, with the mounting plate secured to and mounted on the first and second brackets so as to permit access to the injection site by the autosampler; and securement screws for securing the mounting plate on the brackets.

Abstract: Novel mercapto-acylamino acids useful in the treatment of hypertension and combinations of mercapto-acylamino acids and atrial natriuretic factors or angiotensin converting enzyme inhibitors useful for treating hypertension are disclosed.

Abstract: Antiandrogenic peptidyl esters, particularly tri-peptidyl esters, of the active metabolite of flutamide are disclosed.

Abstract: The use of an angiotensin converting enzyme inhibitor for reducing and controlling the elevation of intraocular pressure associated with the use of corticosteroids is disclosed. Also disclosed are the use of the combination of an angiotensin converting enzyme inhibitor and a steroid, and pharmaceutical compositions comprising the combination.

Abstract: A pharmaceutical composition for the transdermal delivery of loratadine comprising isopropyl myristate and rosemary oil and the method of using such a composition for the treatment of allergic reactions are disclosed.

Abstract: A transdermal nicotine patch comprising an antipruritic to counteract pruritis observed with the transdermal administration of nicotine is disclosed. The patch can be any conventional patch type, e.g., reservoir, adhesive or polymeric matrix.

Abstract: Novel mercapto-acylamino acids useful as analgesic, as well as in the treatment of hypertension and congestive heart failure and combinations of mercapto acylamino acids and atrial natriuretic factors or angiotensin converting enzyme inhibitors useful for treating hypertension and congestive heart failure are disclosed.

Abstract: An insoluble copper-alpha interferon complex useful for injectable pharmaceutical compositions is disclosed.

Abstract: This invention relates to sulfur-substituted phenylacetamides of the formula ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 may be the same or different and are H or CH.sub.3 ; R.sub.4 is SR.sub.5, ##STR2## R.sub.5 and R.sub.6 may be the same or different and are lower alkyl containing 1-4 carbon atoms and R.sub.5 and R.sub.6 may be taken together with S to form a 5-7 member ring; and X.sup.- is a pharmaceutically acceptable anion, which exhibit arrhythmia activity.

Abstract: An insoluble zinc-protamine alpha interferon complex useful as an injectable sustained release dosage form for administering alpha interferon is disclosed.